About me

Prof. Aleix Prat is currently the Head of the Medical Oncology Department of Hospital Clínic Barcelona (Spain), Tenure-Track Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). He obtained his MD degree in 2003 from the University of Barcelona and completed a medical oncology fellowship in 2008 at Vall d´Hebron Institute of Oncology (VHIO). In 2008, Dr. Prat became a postdoctoral research associate at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou. In 2012, he returned to Barcelona as the Head of the Translational Genomics Group at VHIO and later, he moved t

Featured publications

Featured Projects

  • Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

    Principal investigator: Aleix Prat Aparicio
    Funder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede)
    Code: 201935-30-31-32
    Duration: 30/07/2020 - 29/07/2023
  • Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

    Principal investigator: Aleix Prat Aparicio
    Funder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic
    Code: GCAEC19010PRAT
    Duration: 01/12/2019 - 30/11/2024
  • AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

    Principal investigator: Patricia Galvan, Aleix Prat Aparicio
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research
    Code: BCRF_AACR_18_001
    Duration: 01/07/2019 - 30/06/2021
  • Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

    Principal investigator: Aleix Prat Aparicio
    Code: 19-IO-011
    Duration: 01/07/2019 - 30/06/2021
  • Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

    Principal investigator: Aleix Prat Aparicio
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón Salud
    Code: TERAPIA_AMIGOS_18_01
    Duration: 11/02/2019 - 10/02/2022